Introduction {#Sec1}
============

The use of stimulants for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents is known to provide significant short-term improvements both in the core symptoms of the disease (inattention, hyperactivity and impulsivity) and in the behavioural problems associated with it (e.g. aggressive behaviour, depressive mood, anxiety, tics, impaired social functioning and academic productivity) \[[@CR22]\].

Methylphenidate (MPH) is the most commonly prescribed stimulant for children with ADHD. It is characterised by a short half-life of 2--3 h and reaches its maximum effect 1.5--2 h after dosing \[[@CR21]\]; therefore, immediate-release (IR) MPH formulations require repeated administration during the day in order to maintain effectiveness, and 2--3 daily doses are normally needed for most children \[[@CR15]\]. As multiple dosing can cause adherence issues and problems in terms of privacy, stigmatisation by classmates and potential abuse \[[@CR13]\], several long-acting MPH formulations have been developed in the past few years that combine IR and modified-release (MR) components, allowing rapid onset of therapeutic effect and sufficient duration to eliminate the need for additional doses. All available long-acting preparations provide a mixture of MPH-IR and -MR, but differ in the type of modified delivery system used and in the proportion of IR-to-MR components \[[@CR3]\], which results in distinct pharmacokinetic profiles over time; this is reflected by patterns of efficacy and action on behaviour throughout the day that are specific for each long-acting MPH formulation \[[@CR3], [@CR22]\]. Equasym XL^®^[1](#Fn1){ref-type="fn"} (Shire Pharmaceuticals Ireland Limited, Ireland) combines 30% MPH-IR and 70% MPH-MR, producing a fast initial increase in MPH plasma concentration followed by a second increase approximately 3 h later and maintaining therapeutic concentration for about 8 h \[[@CR20], [@CR24]\]; it has been shown to be as effective as MPH-IR given twice daily \[[@CR12]\].

Although different MPH preparations have been compared directly in randomised clinical trials---such as the COMACS study \[[@CR22]\] or the above-mentioned study comparing Equasym XL^®^ and MPH-IR \[[@CR12]\]---empirical data on the effects of different MPH formulations in a natural, real-life setting are scarce. Results from a European open-label study investigating the effectiveness and tolerability of a long-acting MPH formulation (osmotic release oral system \[OROS\] MPH \[Concerta^®^, Janssen-Cilag Ltd, UK\]) in children and adolescents treated previously with MPH-IR revealed that symptom control was maintained or improved after switching to the long-acting formulation; the improvement was more evident to parents than teachers, possibly reflecting increased symptom control in the second part of the day after school \[[@CR17]\]. Another open-label study analysed the effect of abrupt conversion from a stable dose of oral MPH-MR to an MPH transdermal system (Daytrana^®^, Noven Therapeutics LLC, Miami, USA) showing that the transdermal system may further improve ADHD symptoms and quality of life (QoL) when titrated carefully \[[@CR2], [@CR6]\]. However, none of these studies considers different previous therapies and specifically compares their influence on treatment outcome when patients are switched to a different medication.

In another observational study, Döpfner et al. examined the effectiveness and tolerability of an MPH-MR preparation with a 50% IR component (Medikinet^®^ Retard/XL, Medice, Germany) in 447 patients aged 6--17 years with ADHD, and with an indication for treatment with this preparation \[[@CR9]\]. ADHD symptom severity declined significantly. Oppositional behaviour and side effects as rated by parents were also reduced. The authors found the strongest effects in treatment-naïve children, and somewhat weaker effects in children who had received previous treatment with an alternative MPH on the different outcome measures tested.

The OBSEER (OBservation of Safety and Effectiveness of Equasym XL^®^ in Routine care) study \[[@CR8], [@CR19]\] was a non-interventional, post-marketing surveillance study conducted in Germany to evaluate the effectiveness and safety of Equasym XL^®^ under routine care conditions. It included children diagnosed with ADHD or hyperkinetic disorder (HKD) either previously untreated or treated with different formulations of MPH, who started treatment with, or were switched to, Equasym XL^®^.

To test the hypothesis that the extent of improvement reported with Equasym XL^®^ is influenced by the degree of symptom control achieved with a previous medication, patients enrolled in the OBSEER study were stratified according to prior treatment, and changes in ADHD symptoms, other externalising symptoms and QoL were evaluated during treatment with Equasym XL^®^.

Methods {#Sec2}
=======

Participants and study design {#Sec3}
-----------------------------

OBSEER was a post-marketing observational study of Equasym XL^®^, designed primarily to assess effectiveness and safety in clinical practice and conducted in 169 centres in Germany in accordance with local regulations and under the therapeutic responsibility of the attending physicians; ethics or institutional review board approval was not required for this study. Written informed consent was obtained from parents. The study included children aged 6--17 years with a confirmed diagnosis of ADHD according to the Diagnostic and Statistical Manual of the American Psychiatric Association (DSM-IV-TR) \[[@CR1]\] or HKD according to the International Classification of Diseases (ICD-10) \[[@CR25]\], for whom therapy with Equasym XL^®^ was already planned by the treating physician. Details regarding study design and participants are described elsewhere in this supplement \[[@CR8]\]. For this analysis, patients enrolled in the OBSEER study were stratified by pharmacological treatment received prior to study initiation. Four subgroups were considered: treatment-naïve, MPH-IR once daily (o.d.; MPH-IR o.d.), MPH-IR more than o.d. (MPH-IR \>o.d.) and MPH-MR other than Equasym XL^®^. Children who had previously been administered drugs other than MPH or for whom prior treatment was not specified were not included in the analysis.

Outcome measures {#Sec4}
----------------

Measures of ADHD symptoms and QoL in the OBSEER study were obtained using the following tools.German ADHD symptom checklist (Fremdbeurteilungsbogen für Aufmerksamkeitsdefizit-Hyperaktivitätsstörung, FBB-ADHD) \[[@CR5], [@CR10], [@CR11]\]. FBB-ADHD is part of the German diagnostic system for mental disorders in children and adolescents (DISYPS-II) \[[@CR10]\] and assesses 20 symptom items, which are rated by teachers and parents on a scale ranging from 0 = not at all, to 3 = very much, with higher scores indicating more severe symptoms. Nine symptom items are combined into a subscale assessing inattention, and 11 items are combined to assess hyperactivity and impulsivity; the total symptom score covers all 20 symptom items. In addition, four items evaluate functional impairment with respect to school performance, relationship towards adults and children, and the subjective level of suffering (*functional impairment* subscale), and six items assess competences regarding attentive, reflexive and enduring behaviour (*attention*--*reflexivity* subscale).ADHD-Clinical Global Impression--Severity (ADHD-CGI-S). A scale assessing ADHD core symptoms (inattention, hyperactivity and impulsivity) and disease-associated problems (aggressive behaviour, depressive mood, anxiety, tics and learning difficulties).Day profile of ADHD symptoms (DAYAS) \[[@CR4]\]. DAYAS assesses the daily profile of ADHD and other externalising symptoms from early morning until bedtime. A teacher version of the questionnaire (DAYAS-T) considers the first and second part of the morning at school. This complements the parent version (DAYAS-P), which covers the remaining four daily periods: early morning (before school), early afternoon until 4.00 pm, late afternoon until 7.00 pm and evening. The rating scale evaluates six items: (1) hyperactivity, (2) inattention, (3) impulsivity, (4) oppositional behaviour, (5) aggressive behaviour and temper tantrums and (6) a global rating of problem behaviour. A subscale, *ADHD symptoms*, comprises items 1--3, and items 4 and 5 are combined into a second subscale, *oppositional defiant disorder (ODD) symptoms*. For each period, parents and teachers rate each item on a four-point scale using the following values: 0 = not at all; 1 = just a little; 2 = pretty much; 3 = very much.Kinder Lebensqualitätsfragebogen (KINDL). A questionnaire for the assessment of health-related QoL \[[@CR16]\]. This is a short, validated tool comprising 24 items, with six subscales (*physical well*-*being, emotional well*-*being, self*-*esteem, family, friends* and *school*). Three different versions were used according to age group: KID-KINDL (children aged 6--11 years old), the self-reported KIDDO-KINDL (adolescents aged 12--17 years old) and KINDL for parents of patients aged 6--17 years old.

Details about these instruments, as well as their use and results in the OBSEER study, are described elsewhere in this supplement \[[@CR4], [@CR8], [@CR19]\].

Statistical analysis {#Sec5}
--------------------

As described above, the study sample was divided based on previous medication into four subgroups (treatment naïve, MPH-IR o.d., MPH-IR \>o.d. and alternative MPH-MR formulation). Post hoc multivariate analyses of variance (MANOVA) were conducted with the four groups as between-subject factor, and with the repeated assessment at Visits 1, 2 and 3 as within-subject factor. Effect sizes \[[@CR14], [@CR18]\] were calculated post hoc as indicators of symptom change using Cohen's *d* \[[@CR7]\] for dependent samples, by dividing the difference between the means of Visit 1 and Visit 3 with a variable including the pooled standard deviations (SD) for Visits 1 and 3, and the bivariate correlation (*r*) between the two visits, as follows:$$\documentclass[12pt]{minimal}
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Results {#Sec6}
=======

Patient characteristics {#Sec7}
-----------------------

This analysis included 782 of the 852 patients enrolled in the OBSEER study; children for whom the information regarding previous therapy was unclear were not considered, and those treated previously with medications other than MPH were also excluded due to the reduced group size. Baseline characteristics stratified by previous MPH treatment, ADHD diagnosis and daily MPH dosage are presented in Table [1](#Tab1){ref-type="table"}. Statistically significant differences between previous medication subgroups were found for age (MANOVA: *F*(3, 764) = 3.28; *P* = 0.020), with older children in the MPH-IR \>o.d. and MPH-MR subgroups. Between the three subgroups treated previously with MPH, daily MPH dosage also varied significantly (MANOVA: *F*(2, 521) = 64.52; *P* \< 0.001), being highest in the MPH-MR group, followed by the MPH-IR \>o.d. group.Table 1Baseline patient characteristics stratified by previous medicationPrevious treatment (*N* = 782)None (*n* = 208)MPH-IR o.d. (*n* = 101)MPH-IR \>o.d. (*n* = 270)MPH-MR (*n* = 203)Baseline demographics Males, %80.379.280.482.2 Age, years (mean \[SD\])9.76 (2.74)9.78 (2.25)9.94 (2.40)10.46 (2.29)ADHD diagnosis (ICD code), % F90.0: disturbance of activity/attention48.146.556.357.1 F90.1: hyperkinetic conduct disorder33.231.734.835.0 F90.8: other hyperkinetic disorders11.110.96.74.9Daily MPH dosage at Visit 1^a^, mg (mean \[SD\])--14.13 (7.48)23.99 (10.88)29.15 (11.28)*ICD* International Classification of Diseases \[[@CR25]\], *IR* immediate release, *MPH* methylphenidate, *MR* modified release, *o.d.* once daily, *SD* standard deviation^a^Prior to treatment with Equasym XL^®^

ADHD and ODD symptoms {#Sec8}
---------------------

Physician (ADHD-CGI-S), parent and teacher ratings (FBB-ADHD) of ADHD symptoms at each study visit stratified by prior treatment, MANOVA results (group effect and group-by-time interaction effect) and effect sizes (Cohen's *d*) are shown in Table [2](#Tab2){ref-type="table"}. For the FBB-ADHD scale, the subscales *inattention* and *hyperactivity/impulsivity* gave similar results and are, therefore, presented combined as total symptom score, along with the functional impairment and attentive, reflexive and enduring behaviour (*attention*--*reflexivity* subscale) scores.Table 2ADHD symptoms rated by physicians, parents and teachers stratified by previous medication with main group effect, group-by-time interaction effect (MANOVA) and effect sizes (Cohen's *d*)Outcome measurePrevious treatment*n*Visit 1Visit 2Visit 3MANOVA groupMANOVA group-by-time interactionEffect sizeMean (SD)Mean (SD)Mean (SD)*FPFP*Cohen's *d* (Visit 1--Visit 3)*Clinical rating (CGI*--*S)*Global impressionNone1542.27 (0.57)1.40 (0.66)1.00 (0.63)3.350.0199.810.0001.73MPH-IR o.d.772.10 (0.66)1.38 (0.67)0.96 (0.75)1.29MPH-IR \>o.d.2131.88 (0.70)1.26 (0.73)1.02 (0.61)1.11MPH-MR1641.88 (0.64)1.36 (0.69)1.24 (0.65)0.76*Parent rating (FBB*-*ADHD)*Total scoreNone1851.81 (0.62)1.16 (0.61)0.95 (0.55)3.660.0129.970.0001.41MPH-IR o.d.861.73 (0.61)1.19 (0.60)1.07 (0.61)1.15MPH-IR \>o.d.2341.49 (0.63)1.06 (0.55)0.98 (0.52)0.85MPH-MR1651.54 (0.57)1.25 (0.58)1.11 (0.58)0.79Functional impairmentNone1852.06 (0.65)1.34 (0.69)1.04 (0.64)8.280.00011.190.0001.36MPH-IR o.d.861.87 (0.73)1.39 (0.69)1.24 (0.71)0.81MPH-IR \>o.d.2331.65 (0.75)1.19 (0.72)1.05 (0.72)0.70MPH-MR1651.78 (0.72)1.59 (0.73)1.36 (0.73)0.53Attentive, reflexive and enduring behaviourNone1850.72 (0.57)1.16 (0.64)1.32 (0.59)2.930.0336.320.0000.93MPH-IR o.d.870.80 (0.60)1.11 (0.60)1.17 (0.71)0.54MPH-IR \>o.d.2331.01 (0.64)1.21 (0.66)1.27 (0.67)0.37MPH-MR1650.91 (0.63)1.04 (0.60)1.10 (0.63)0.27*Teacher rating (FBB*-*ADHD)*Total scoreNone1401.56 (0.70)0.98 (0.61)0.74 (0.49)0.660.57914.160.0001.38MPH-IR o.d.661.25 (0.74)0.97 (0.62)0.91 (0.63)0.51MPH-IR \>o.d.1621.16 (0.71)1.00 (0.63)0.88 (0.62)0.43MPH-MR1241.20 (0.62)1.07 (0.63)0.99 (0.58)0.41Functional impairmentNone1411.82 (0.82)1.21 (0.77)0.86 (0.65)2.820.03911.220.0001.17MPH-IR o.d.651.45 (0.89)1.12 (0.77)1.03 (0.79)0.49MPH-IR \>o.d.1601.25 (0.88)1.06 (0.82)0.93 (0.82)0.40MPH-MR1251.42 (0.85)1.28 (0.84)1.12 (0.74)0.42Attentive, reflexive and enduring behaviourNone1390.80 (0.54)1.15 (0.61)1.32 (0.64)0.750.5236.460.0000.78MPH-IR o.d.660.99 (0.68)1.12 (0.71)1.21 (0.70)0.33MPH-IR \>o.d.1581.09 (0.65)1.22 (0.64)1.25 (0.62)0.29MPH-MR1211.08 (0.62)1.14 (0.64)1.18 (0.62)0.20*CGI*--*S* Clinical Global Impression-Severity (ADHD core symptoms and associated problems), *FBB*-*ADHD* Fremdbeurteilungsbogen für Aufmerksamkeitsdefizit-Hyperaktivitätsstörung, *IR* immediate release, *MANOVA* multivariate analysis of variance, *MPH* methylphenidate, *MR* modified release, *o.d.* once daily

The main effect of time was highly significant on all outcome measures (data not shown), indicating significant symptom improvement across the three assessment points. Significant between-group effects were also observed on most variables, and group-by-time interactions were significant for all outcomes analysed, indicating different effects for different previous medications (Table [2](#Tab2){ref-type="table"}).

Reductions in ADHD symptoms during treatment with Equasym XL^®^ (from Visit 1 to Visit 3) as assessed by clinicians on the ADHD-CGI-S scale are shown as effect sizes (Cohen's *d*) in Fig. [1](#Fig1){ref-type="fig"}a. The largest reduction was observed in the treatment-naïve subgroup (*d* = 1.73), followed in order of decreasing reduction by MPH-IR o.d., MPH-IR\> o.d. and MPH-MR (*d* = 0.76). Although the effect sizes for FBB-ADHD parameters were somewhat smaller (Fig. [1](#Fig1){ref-type="fig"}b), the same profile was observed for parent and teacher ratings (FBB-ADHD total score), with the largest changes being found in the subgroup without prior medication. For teacher ratings, effect sizes in the subgroups with previous medication were smaller than for parent ratings.Fig. 1Reduction in **a** clinician-rated (CGI-S) and **b** parent- and teacher-rated ADHD symptoms (FBB-ADHD total score) from Visit 1 to Visit 3 in different previous medication subgroups, expressed as effect size (Cohen's *d*). *CGI*--*S* Clinical Global Impressions--Severity, *FBB*-*ADHD* Fremdbeurteilungsbogen für Aufmerksamkeitsdefizit-Hyperaktivitätsstörung, *IR* immediate release, *MR* modified release, *MPH* methylphenidate, *o.d.* once daily

Parent and teacher ratings of ADHD and ODD symptoms (DAYAS-P and DAYAS-T total scores) at each study visit during different periods of the day, with the corresponding MANOVA results and effect sizes, are shown in Table [3](#Tab3){ref-type="table"}; separate analyses for the DAYAS *ADHD* and *ODD symptoms* subscales gave similar results (data not shown). Significant group-by-time interactions were observed for all parts of the day, except the evening (DAYAS-P), when no significant differences between subgroups were found. Figure [2](#Fig2){ref-type="fig"} illustrates the reductions in ADHD and ODD symptoms during treatment with Equasym XL^®^ (effect sizes) on the DAYAS-P and DAYAS-T scales. For parent ratings, the largest reductions in ADHD and ODD symptoms between Visit 1 and Visit 3 were observed in the early and late afternoon for all subgroups, except MPH-MR, while changes in the morning and evening were generally smaller. The most marked differences between groups were also found during the early and late afternoon, with symptom reduction most pronounced in the subgroup with no previous medication. For teacher ratings, the subgroup without previous medication showed substantial improvements in ADHD and ODD symptoms both in the first and second half of the school morning. Changes were moderate in the MPH-IR subgroups and smaller in the MPH-MR subgroup, in particular during the first half of the morning.Table 3ADHD and ODD symptoms rated by teachers and parents for different parts of the day (DAYAS total score) stratified by previous medication with main group effect, group-by-time interaction effect (MANOVA) and effect sizes (Cohen's *d*)Outcome measurePrevious treatment*N*Visit 1Visit 2Visit 3MANOVA groupMANOVA group-by-time interactionEffect sizeMean (SD)Mean (SD)Mean (SD)*FPFP*Cohen's *d* (Visit 1--Visit 3)*Parent rating (DAYAS*-*P total score)*Morning before schoolNone1821.29 (0.75)0.95 (0.65)0.88 (0.63)11.150.0003.450.0020.60MPH-IR o.d.861.20 (0.73)0.97 (0.66)0.95 (0.71)0.37MPH-IR \>o.d.2241.33 (0.79)0.97 (0.71)0.97 (0.69)0.53MPH-MR1631.54 (0.73)1.39 (0.77)1.23 (0.79)0.49AfternoonNone1771.72 (0.70)1.07 (0.65)1.07 (0.65)2.990.0148.770.0001.24MPH-IR o.d.861.54 (0.66)1.15 (0.64)1.15 (0.64)0.75MPH-IR \>o.d.2171.36 (0.67)1.01 (0.62)1.01 (0.62)0.67MPH-MR1631.43 (0.60)1.17 (0.61)1.17 (0.61)0.63Late afternoonNone1811.69 (0.73)1.27 (0.67)1.14 (0.60)1.920.1252.910.0080.88MPH-IR o.d.871.61 (0.69)1.29 (0.64)1.21 (0.70)0.59MPH-IR \>o.d.2261.54 (0.68)1.23 (0.66)1.17 (0.65)0.54MPH-MR1641.61 (0.59)1.43 (0.57)1.31 (0.64)0.45EveningNone1791.38 (0.80)1.21 (0.72)1.10 (0.66)6.040.0000.920.4800.38MPH-IR o.d.871.50 (0.75)1.22 (0.74)1.22 (0.77)0.37MPH-IR \>o.d.2261.43 (0.72)1.22 (0.72)1.15 (0.72)0.41MPH-MR1641.64 (0.67)1.49 (0.70)1.36 (0.71)0.44*Teacher rating (DAYAS*-*T total score)*Morning first halfNone1401.31 (0.71)0.81 (0.57)0.59 (0.45)1.220.30110.840.0000.99MPH-IR o.d.641.06 (0.75)0.86 (0.70)0.74 (0.68)0.49MPH-IR \>o.d.1620.91 (0.74)0.78 (0.63)0.72 (0.63)0.28MPH-MR1220.96 (0.68)0.93 (0.70)0.87 (0.65)0.14Morning second halfNone1381.64 (0.81)1.06 (0.66)0.83 (0.58)1.060.3668.430.0001.09MPH-IR o.d.611.27 (0.74)1.01 (0.69)0.94 (0.74)0.46MPH-IR \>o.d.1531.29 (0.81)1.07 (0.70)0.96 (0.69)0.45MPH-MR1161.36 (0.78)1.20 (0.79)1.10 (0.74)0.39*DAYAS*-*P/*-*T* day profile of ADHD symptoms---parent/teacher rating, *IR* immediate release, *MANOVA* multivariate analysis of variance, *MPH* methylphenidate, *MR* modified release, *o.d.* once daily, *ODD* oppositional-defiant disorder, *SD* standard deviationFig. 2Reduction in parent (morning before school, afternoon, late afternoon and evening) and teacher ratings (first half of school morning and second half of school morning) of ADHD and ODD symptoms for different parts of the day (DAYAS total score) by previous medication subgroup, expressed as effect size (Cohen's *d*) from Visit 1 to Visit 3. *DAYAS* day profile of ADHD symptoms, *IR* immediate release, *MR* modified release, *MPH* methylphenidate, *o.d.* once daily, *ODD* oppositional-defiant disorder

Quality of life {#Sec9}
---------------

Parent (KINDL) and patient (KID-KINDL, 6--11 years old) ratings of QoL stratified by previous medication, with main effects of group and group-by-time interactions (MANOVA) and effect sizes (Cohen's *d*), are reported in Table [4](#Tab4){ref-type="table"}. Ratings by patients aged 12--17 years on the KIDDO-KINDL scale were not considered because subgroups in this age range were too small for this type of analysis. The main effects of time were highly significant for all outcome parameters (data not shown). For parent-rated QoL (KINDL), significant group-by-time interactions were found for the total score and the subscales *self*-*esteem*, *friends* and *school*, but not for *physical well*-*being*, *emotional well*-*being* and *family*. Effect sizes for the total score were in the moderate-to-large (≥0.5) range, with largest changes in the treatment-naïve and MPH-IR o.d. subgroups. Effect sizes for MPH-IR \>o.d. and MPH-MR were smaller and very similar. In patient-rated QoL (KID-KINDL), significant group-by-time interactions were found for the total score and the subscales *self*-*esteem*, *family*, *friends* and *school*, but not for *physical well*-*being* and *emotional well*-*being*. Effect sizes for the total score varied from small to large, with most pronounced changes in the treatment-naïve subgroup. Effect sizes for the other subgroups were smaller and very similar.Table 4Parent (KINDL) and child (KID-KINDL) ratings of QoL stratified by previous medication with main group effect, group-by-time interaction effect (MANOVA) and effect sizes (Cohen's *d*)Outcome measurePrevious medication*N*Visit 1Visit 3MANOVA groupMANOVA group-by-time interactionEffect sizeMean (SD)Mean (SD)*FPFP*Cohen's *d* (Visit 1--Visit 3)*Parent rating of QoL (KINDL)*Total scoreNone15861.41 (13.82)72.34 (11.25)2.510.5805.130.0270.90MPH-IR o.d.7460.61 (12.92)70.62 (12.53)0.74MPH-IR \>o.d.19765.40 (13.32)72.15 (11.39)0.56MPH-MR13662.90 (11.93)69.24 (11.50)0.53Physical well-beingNone16372.84 (18.54)78.83 (16.62)0.160.9210.340.7940.33MPH-IR o.d.7471.28 (15.99)78.21 (18.22)0.38MPH-IR \>o.d.20172.08 (18.83)79.48 (14.09)0.42MPH-MR13771.03 (17.30)79.09 (17.01)0.42Emotional well-beingNone16367.73 (17.34)75.61 (14.32)1.050.3710.850.4670.46MPH-IR o.d.7465.03 (17.58)73.73 (16.16)0.50MPH-IR \>o.d.20169.68 (17.48)75.28 (15.50)0.31MPH-MR13767.43 (16.72)74.18 (14.48)0.45Self-esteemNone16353.09 (19.59)65.50 (15.81)4.000.0085.390.0010.66MPH-IR o.d.7451.41 (18.00)62.33 (16.32)0.60MPH-IR \>o.d.20158.71 (17.64)65.53 (16.31)0.39MPH-MR13754.87 (16.63)59.87 (15.39)0.29FamilyNone16360.20 (20.46)69.93 (16.54)2.430.0652.150.9300.56MPH-IR o.d.7459.68 (20.03)68.22 (18.66)0.46MPH-IR \>o.d.20165.05 (19.14)71.57 (16.62)0.37MPH SR13762.01 (17.87)66.94 (16.50)0.29FriendsNone16359.83 (20.61)70.64 (16.79)0.950.4163.820.0100.63MPH-IR o.d.7457.15 (19.48)69.34 (16.62)0.57MPH-IR \>o.d.20163.36 (20.65)68.81 (18.78)0.31MPH-MR13759.49 (21.07)67.29 (17.60)0.42SchoolNone15856.34 (19.69)73.62 (16.01)3.190.02310.950.0000.87MPH-IR o.d.7459.12 (18.51)71.90 (15.58)0.67MPH-IR \>o.d.19764.73 (17.38)73.28 (15.57)0.49MPH-MR13661.93 (16.42)68.01 (17.05)0.36*Patient rating of QoL (KID*-*KINDL)*Total scoreNone12064.00 (12.76)74.56 (10.04)0.490.6904.870.0020.91MPH-IR o.d.6068.37 (12.91)72.97 (12.17)0.33MPH-IR \>o.d.15767.00 (14.13)73.84 (12.30)0.48MPH-MR8367.20 (12.25)71.27 (11.87)0.31Physical well-beingNone12175.29 (18.17)80.73 (15.47)1.050.3700.850.4680.33MPH-IR o.d.6271.51 (14.92)77.52 (15.45)0.33MPH-IR \>o.d.15873.60 (18.01)79.51 (16.13)0.30MPH-MR8574.39 (16.22)76.59 (17.35)0.11Emotional well-beingNone12170.14 (16.37)77.01 (13.72)1.070.3620.850.4700.41MPH-IR o.d.6270.60 (16.43)76.41 (14.20)0.32MPH-IR \>o.d.15873.37 (17.32)78.24 (15.08)0.27MPH-MR8571.84 (16.47)74.78 (15.92)0.16Self-esteemNone12153.87 (20.16)66.77 (17.86)0.760.5204.400.0050.66MPH-IR o.d.6261.26 (18.99)64.58 (21.04)0.15MPH-IR \>o.d.15858.95 (21.11)67.29 (20.89)0.35MPH-MR8559.63 (18.02)62.94 (19.52)0.17FamilyNone12164.57 (19.46)75.03 (15.21)1.030.3783.140.0250.64MPH-IR o.d.6272.78 (18.67)74.29 (17.20)0.09MPH-IR \>o.d.15868.95 (20.43)75.59 (16.39)0.33MPH-MR8466.99 (19.76)74.85 (16.12)0.37FriendsNone12164.72 (20.29)74.09 (17.72)0.140.9372.200.0880.53MPH-IR o.d.6168.03 (20.89)74.25 (21.17)0.26MPH-IR \>o.d.15867.38 (22.90)72.46 (20.14)0.24MPH--MR8569.12 (20.12)71.32 (17.18)0.11SchoolNone12054.27 (22.47)72.41 (16.10)0.460.7116.460.0000.82MPH-IR o.d.6162.77 (21.53)68.95 (18.92)0.29MPH-IR \>o.d.15760.20 (21.73)70.08 (18.53)0.43MPH-MR8462.15 (19.37)68.63 (18.70)0.30*IR* immediate release, *KINDL* Kinder Lebensqualitätsfragebogen, *MANOVA* multivariate analysis of variance, *MPH* methylphenidate, *MR* modified release, *o.d.* once daily, *QoL* quality of life, *SD* standard deviation

Figure [3](#Fig3){ref-type="fig"}a illustrates the improvements in parent-rated QoL (KINDL) by subgroup from Visit 1 to Visit 3 (effect sizes) on the three subscales that showed significant group-by-time interactions (*self*-*esteem*, *friends* and *school*).Fig. 3Improvement in QoL from Visit 1 to Visit 3 according to **a** parent (KINDL) and **b** patient (KID-KINDL) ratings (subscales with significant group-by-time interactions only) by previous medication subgroup, expressed as effect size (Cohen's *d*). *KINDL* Kinder Lebensqualitätsfragebogen, *IR* immediate release, *MR* modified release, *MPH* methylphenidate, *o.d.* once daily, *QoL* quality of life

The largest effect sizes were observed for *school*, except for MPH-MR, which had the largest effect on *friends*. In all subscales, the treatment-naïve and MPH-IR o.d. subgroups showed the most dramatic improvements during treatment with Equasym XL^®^; in the other subgroups, effect sizes were smaller and comparable across all three subscales.

Similarly, Fig. [3](#Fig3){ref-type="fig"}b shows the improvements in patient-rated QoL (KID-KINDL) from Visit 1 to Visit 3 for the four subscales with significant group-by-time interactions (*self*-*esteem, friends, school* and *family*).

Again, in all subgroups, the largest effect sizes were observed for *school* except for MPH-MR, which had the largest effect on *family*. The treatment-naïve and MPH-IR o.d. subgroups showed the most dramatic improvements during treatment with Equasym XL^®^ in all subscales. In the other subgroups, effect sizes were smaller and comparable across subscales.

Discussion {#Sec10}
==========

The hypothesis for this post hoc analysis of the data obtained from the OBSEER study was that the effect size of the improvements observed with Equasym XL^®^, as assessed by rating of ADHD symptoms, ODD symptoms and QoL, should depend on the degree of symptom control achieved with the previous medication. Following this hypothesis, the strongest effect of Equasym XL^®^ should be observed in patients without previous medication, while substantial but smaller effects should be observed in children treated previously with MPH-IR o.d. Effects in the MPH-IR \>o.d. or MPH-MR subgroups should be more moderate and somewhat lower than MPH-IR o.d.

As expected, during Equasym XL^®^ treatment in the OBSEER study, the largest changes in ADHD symptoms, ODD symptoms and QoL, were observed in the treatment-naïve subgroup, followed by patients treated previously with MPH-IR o.d., MPH-IR \>o.d. and MPH-MR; this was consistently confirmed on all of the rating scales used for ADHD symptoms here, specifically CGI-S (clinical rating), FBB-ADHD and DAYAS (parent and teacher ratings), as well as on the KINDL scales of self-esteem, friends and school (parent and patient ratings) and family (patient ratings only) for QoL.

The effect sizes for ADHD symptoms (FBB-ADHD) in the subgroup without previous medication were approximately 1.4 for both parent and teacher ratings, which is very close to the results obtained in a recent meta-analysis of the efficacy of short-acting MPH \[[@CR23]\]. In this meta-analysis, the standardised pre- to post-assessment score change (mean weighted Cohen's *d*) was 1.53 (95% confidence intervals \[CI\]: 1.23--1.82) for parent ratings and 1.83 (95% CI: 1.43--2.12) for teacher ratings. Thus, similar changes during MPH treatment can be found in treatment-naïve groups in both randomised controlled trials and observational trials. Conversely, in another observational study analysing the effectiveness of a different long-acting MPH formulation (Medikinet^®^ Retard/XL) \[[@CR9]\], the effect size for parent-rated ADHD and ODD symptoms (DAYAS total score) was 1.1 in the subgroup without previous medication, which is somewhat lower than the effects observed in the present study on the FBB-ADHD scale. However, in the present study, slightly lower effects were also found on the DAYAS scale at different periods throughout the day, with the highest effect size (1.24) in the afternoon.

It is interesting to note that on the FBB-ADHD scale, effect sizes in the subgroups with previous medication were smaller in teacher ratings than in parent ratings; this may be due to the fact that in Germany, teachers observed the children only in the morning, when the differences between short- and long-acting medication regimens may be less apparent and, consequently, possibly less perceptible to them than they were to parents. In fact, as shown by its pharmacokinetic profile, Equasym XL^®^ is characterised by consistent MPH plasma concentrations and therefore has a consistent effect for over 8 h after administration \[[@CR24]\]; thus, differences relative to short-acting medications would be expected, especially in the afternoon. This is supported by the results obtained on the DAYAS scale, where the strongest symptom reduction compared with previous medication was observed in the afternoon (parent ratings), followed by the morning during school (teacher ratings). The effects in the evening were smaller because the effects of all medications usually diminish and wear off in this part of the day*.*

To our knowledge, this is the first observational study assessing the differential effects of prior medication status on patient QoL in both parent and patient ratings. The results show differential improvements after switching to Equasym XL^®^ in several of the QoL domains that are most affected in children with ADHD: self-esteem, friends and school (parent and patient ratings) and family (patient ratings only). The effect sizes for these QoL domains in the treatment-naïve group were about half of those obtained for symptom control (FBB-ADHD); however, they were still in the moderate-to-large range. The effects in the subgroups with previous treatment were smaller but mostly still substantial (≥0.30).

The main limitation of this analysis is that, being based on data from an observational study, there was no randomisation, and the subgroups examined were natural groups with different prior treatments. Therefore, it should be taken into account that factors other than previous medication itself may have contributed to the differences observed. Selection bias may also have had an effect on the results of this study, as patients were selected and switched to Equasym XL^®^ only if the efficacy of the previous medication was insufficient, while children for whom treatment with other MPH formulations was successful were not included. It should be considered, however, that compared with randomised clinical trials, the information gained from observational studies reflects real-life situations, and therefore are more directly applicable and extendable to daily clinical practice.

In summary, the effects of Equasym XL^®^ were greatest for treatment-naïve patients and similar to those found in randomised clinical trials. However, improvements in ADHD symptoms, ODD symptoms and QoL were also observed in subgroups with prior treatment. This suggests that switching to Equasym XL^®^ may be beneficial even in patients who only achieve suboptimal effects with a different stimulant medication, leading to improved symptom control and QoL, and reduced functional impairment.
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